The immunotherapy against programmed cell death protein 1 (programmed death-1, PD-1) and its ligand 1 (programmed death ligand-1, PD-L1) has been used in NSCLC, and good results have been achieved in patients, especially in individuals with high expression of PD-L1 (4, 5). Here, PDCD1 is linked to non-small cell lung carcinoma.